85 results
8-K
EX-99.1
BBIO
BridgeBio Pharma Inc
2 May 24
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
7:31am
liabilities
Deferred revenue
2029 Notes, net
2027 Notes, net
Term loan, net
Other long-term liabilities
Redeemable convertible noncontrolling interests
Total
424B5
BBIO
BridgeBio Pharma Inc
6 Mar 24
Prospectus supplement for primary offering
5:15pm
or long-term residents of the United States;
persons subject to the alternative minimum tax;
persons holding our common stock as part of a hedge
8-K
EX-1.1
ul6smmqk6g b1y97w
6 Mar 24
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
5:13pm
424B5
shn 980i4ba64wk
4 Mar 24
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
b126 y52k8r7no9y04i
22 Feb 24
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
7:31am
8-K
EX-99.1
lrh84e1
8 Jan 24
Other Events
5:14pm
8-K
EX-99.1
qzniskjdsfklo7
2 Nov 23
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
7:31am
8-K
EX-99.1
fxdg6dwq4
25 Sep 23
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
4:00pm
8-K
EX-99.1
kj8fucdzpjb4
3 Aug 23
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
7:32am
S-3ASR
EX-1.2
yb06rzoxb4b
4 May 23
Automatic shelf registration
4:55pm
8-K
EX-99.1
zrn4blmpaz646nc6f
4 May 23
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
7:46am
8-K
EX-99.1
0o57m3evdsr v5
3 Nov 22
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
5:05pm